Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9055480 | 0.83 | MAPT (0.46) | MEN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL5803864 | 0.78 | CA2 (0.40) | CA2SMN1; SMN2KMT2AALDH1A1TSHR | |
| SCHEMBL24311920 | 0.78 | SMN1; SMN2 (0.43) | CA2SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL11384694 | 0.75 | KDM4E (0.36) | CA2SMN1; SMN2MEN1KMT2ACYP2D6 | |
| SCHEMBL14587066 | 0.75 | CACNA1G (0.44) | SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL4287696 | 0.74 | KMT2A (0.39) | CA2MEN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL14601299 | 0.69 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2ACHRNA7TSHR | |
| SCHEMBL1315164 | 0.69 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2ACHRNA7TSHR | |
| SCHEMBL11951038 | 0.69 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2ACHRNA7TSHR | |
| SCHEMBL1315523 | 0.69 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2ACHRNA7TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259306-A1 | DESAZADESFERROTHIOCIN ANALOGUES AS METAL CHELATION AGENTS | FERROKIN BIOSCIENCES INC (US) | 2015-09-17 | — | — | US | disclosed |
| US-9045440-B2 | Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents | FERROKIN BIOSCIENCES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130053387-A1 | DESAZADESFERROTHIOCIN AND DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | FerroKin BioScience, Inc. (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2011140232-A2 | DESAZADESFERROTHIOCIN AND DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | FERROKIN BIOSCIENCES, INC (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110275636-A1 | DESAZADESFERROTHIOCIN AND DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | FERROKIN BIOSCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2034994-A2 | NF-KAPPA B INHIBITORS AND USES THEREOF | The Board Of Trustees Operating Michigan State University (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007133790-A2 | NF-ϰB INHIBITORS AND USES THEREOF | THE BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1532117-A4 | MULTI-SUBSTITUDED IMIDAZOLINES AND METHOD OF USE THEREOF | UNIV MICHIGAN STATE (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1532117-A1 | MULTI-SUBSTITUDED IMIDAZOLINES AND METHOD OF USE THEREOF | Michigan State University (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2003101969-A1 | MULTI-SUBSTITUDED IMIDAZOLINES AND METHOD OF USE THEREOF | MICHIGAN STATE UNIVERSITY (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275636-A1 | DESAZADESFERROTHIOCIN AND DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | SLC39A14, SLC40A1, FTH1 | CA2 2273/4885SMN1; SMN2 1785/4885MEN1 1396/4885 |
| US-20130053387-A1 | DESAZADESFERROTHIOCIN AND DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS | SLC39A14, SLC40A1, FTH1 | CA2 2273/4885SMN1; SMN2 1785/4885MEN1 1396/4885 |
| US-20150259306-A1 | DESAZADESFERROTHIOCIN ANALOGUES AS METAL CHELATION AGENTS | SLC40A1, SLC39A14, HAMP | CA2 2168/4885SMN1; SMN2 2001/4885MEN1 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.